Neuralstem (CUR) Announces Presentation of NSI-189 Preclinical Data at RRS Annual Meeting
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Neuralstem, Inc. (Nasdaq: CUR) announced the presentation of the poster entitled, “Reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound NSI-189,” at the Radiation Research Society Annual Meeting on October 19th. The preclinical study data concluded that NSI-189 provided treatment benefits in the reversal of radiation-induced cognitive deficits.
Research led by Charles Limoli, Ph.D. at University of California, Irvine, showed that treatment of gamma-irradiated rats with NSI-189 daily for 30 days ameliorated radiation-induced impairments in hippocampal- and frontal cortex-dependent episodic and spatial memory functions. Additionally, NSI-189 treatment preserved hippocampal neurogenesis at the pre-irradiation level. Adult rats (n=16/group) were irradiated with clinically relevant dose of cranial irradiation, and then 24-hours later, were started on oral administration of either placebo, or NSI-189 (30mg/kg/day), for 30 days. They were periodically assessed by multiple cognitive tasks The animals on placebo showed significant impairments in performances across all tasks, an effect that was reversed by treatment with NSI-189.
“These new data suggest NSI-189’s potential applicability to protect the brain against permanent cognitive impairment in cancer patients undergoing radiation therapy,” said Dr. Limoli, Professor, Radiation Oncology, University of California, Irvine.
“We are excited by the prospect of extending NSI-189’s neurogenic benefits to improving cognition, added Dr. Karl Johe, Ph.D., Chief Scientific Officer of Neuralstem, and a study author. “After observing NSI-189’s encouraging results in Phase 1b major depressive disorder (MDD) study, we are currently evaluating its potential efficacy as an antidepressant in a larger Phase 2 MDD study. With these new preclinical data, we now plan to explore NSI-189’s utility to treat or protect against cognitive impairment in various indications, such as radiation-induced brain injuries incurred during cancer treatment.”
Radiation therapy (RT) is standard treatment for cancers in the brain and is associated with cognitive dysfunction, particularly in children, resulting in loss of working memory or progressive dementia.
To see the poster, please go visit publications at Neuralstem.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vanda Pharma (VNDA) Enters Settlement with Apotex; Fanapt Licensing Agreement Entered
- Adams Resources (AE) Appoints New CFO
- Dataram (DRAM) Issues Update on Activity of Acquisition Target U.S. Gold Corp.
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!